SCHEMBL3777237

SCHEMBL3777237

COc1ccc(CC(=O)N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.64
ALDH1A1 P00352 7/20 0.64
KMT2A Q03164 3/20 0.64
TSHR P16473 1/20 0.64
MAPT P10636 2/20 0.58
KDM4E B2RXH2 3/20 0.57
HPGD P15428 4/20 0.55
GAA P10253 1/20 0.55
SIGMAR1 Q99720 1/20 0.54
GFER P55789 1/20 0.52
LMNA P02545 1/20 0.52
RAB9A P51151 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.51
ACHE P22303 1/20 0.51
HSD17B10 Q99714 2/20 0.50
CCR3 P51677 1/20 0.49
ORAI1 Q96D31 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767694 0.89 ALDH1A1 (0.52) SMN1; SMN2ALDH1A1KMT2ATSHRMAPT
SCHEMBL3767486 0.87 ALDH1A1 (0.61) SMN1; SMN2ALDH1A1KMT2ATSHRKDM4E
SCHEMBL3770061 0.87 SIGMAR1 (0.63) ALDH1A1KMT2ATSHRMAPTKDM4E
SCHEMBL3767582 0.87 ALDH1A1 (0.65) ALDH1A1KMT2ATSHRKDM4EGAA
SCHEMBL3767766 0.86 ACHE (0.68) SMN1; SMN2ALDH1A1KMT2ATSHRKDM4E
SCHEMBL3763175 0.86 GAA (0.60) SMN1; SMN2ALDH1A1KMT2ATSHRMAPT
SCHEMBL13005925 0.86 KMT2A (0.57) ALDH1A1KMT2ATSHRKDM4EHPGD
SCHEMBL3775904 0.86 HRH3 (0.54) SMN1; SMN2ALDH1A1KMT2ATSHRKDM4E
SCHEMBL3780606 0.86 HTT (0.57) ALDH1A1KMT2ATSHRKDM4EHPGD
SCHEMBL3775691 0.85 ALDH1A1 (0.61) SMN1; SMN2ALDH1A1KMT2ATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 SMN1; SMN2 4282/4885ALDH1A1 1210/4885KMT2A 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.